Payment overview · 2025
General Payments
$2,572.84
71 reported records · 16 companies
Healthcare provider profile · identity verified
David Hardy, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · VALDOSTA, GA · NPI 1548467939
Verified facts
What the public records show
CMS Open Payments records show David Hardy, M.D. received $2,572.84 in general payments during 2025 across 71 reported records.
W. L. Gore & Associates, Inc. accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $1,385.48 | 53.9% | 30 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $278.98 | 10.8% | 8 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $249.37 | 9.7% | 12 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $160.32 | 6.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $145.60 | 5.7% | 5 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $89.21 | 3.5% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $81.00 | 3.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $54.26 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.03 | 1.0% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $19.62 | 0.8% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $17.85 | 0.7% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $16.45 | 0.6% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $15.66 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.65 | 0.5% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $12.82 | 0.5% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $7.54 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,619.36 | 67 |
| Travel and Lodging | $953.48 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $1,240.66 | 14 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $249.37 | 12 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $182.84 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $160.32 | 4 | 2025 |
Source payment records
|
|||||
| ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Normalized: enroute enflate transcarotid rx balloon dilatation catheter |
Device | Boston Scientific Corporation | $96.14 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $89.87 | 3 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $89.21 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $81.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $60.54 | 6 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $32.69 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $22.25 | 4 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $12.82 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $8.86 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $8.60 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $7.58 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $7.54 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $4.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 142 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 41 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 16 |
| Prednisone | Prednisone | 16 | 12 |
| Eliquis | Apixaban | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,572.84 · 71 records | W. L. Gore & Associates, Inc. | AQUACEL AG+ EXTRA, ARTIX MT, AZUR CX DETACHABLE, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter, ENROUTE Transcarotid Neuroprotection System, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWRUNNER, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft, GORE TAG Thoracic Branch Endoprosthesis, GORE VIABAHN Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, Indigo System, Kerecis GraftGuide, Kerecis SurgiClose, PREVELEAK, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, TREO ABDOMINAL STENT-GRAFT SYSTEM | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error